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Abstract
Background: The approaches to the diagnosis and treatment of chronic spontaneous urticaria (CSU) differ in various
parts of the world. We sought to determine the adherence to international and national urticaria guidelines as well as
the motives to deviate from the guidelines among physicians worldwide.
Methods: A web-based questionnaire was created and launched via e-mail by the World Allergy Organization (WAO) to
representatives of all WAO Member Societies, the members of the American Academy of Allergy, Asthma & Immunology
(AAAAI) and the members of the WAO Junior Members Group (JMG), regardless of the specialty, affiliation, or nationality
in March 2017.
Results: We received 1140 completed surveys from participating physicians from 99 countries. Virtually all participants
(96%) were aware of at least one urticaria guideline and reported that they follow a guideline. However, one in five
physicians who follow a guideline (22%) reported to deviate from it. Reliance on own clinical experience is the most
frequent reason for deviation from guidelines or not following them (44%). Young (< 40 years) and less experienced
physicians more often follow a guideline and less often deviate than older and experienced ones. Physicians who follow
a urticaria guideline showed higher rates of routinely ordering a complete blood count, the erythrocyte sedimentation
rate, C-reactive protein, anti-thyroid antibodies, and thyroid-stimulating hormone and of performing the autologous
serum skin test as compared to those who do not. Physicians who follow a urticaria guideline showed higher rates of
using second generation antihistamines as their first-line treatment of CSU (p = 0.001) and more frequently observed
higher efficacy of these drugs (or had more confidence that it would work, p < 0.019) as compared to those who do not
follow the guidelines.
Conclusions: Physicians’ characteristics (e.g. age, clinical experience, and specialty) and country specifics and regional
features (e.g. availability of drugs for CSU treatment) importantly influence adherence to urticaria guidelines and CSU
patient care and should be addressed in more detail in future research.
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Background
Chronic spontaneous urticaria (CSU) is a mast
cell-driven disease that is defined as the occurrence of
wheals, angioedema, or both for more than 6 weeks due
to known or unknown causes [1]. CSU affects up to 1%
of the general population [2, 3]. It exerts a devastating
impact on patients’ quality of life [4, 5].
The approaches to the diagnostic workup and treatment
of CSU patients differ in various parts of the world, and
there are discrepancies between national consensus papers
and guidelines and the international EAACI/GA2LEN/
EDF/WAO guideline [1, 6, 7]. The impact of guidelines on
the diagnostic workup and treatment strategy selection in
every day clinical practice needs further research. How
many physicians know urticaria guidelines? How many
physicians use them to guide their clinical practice? What
are the reasons for not following the available guidelines?
What is the impact of following the guidelines on the
quality of care for urticaria patients? These questions need
to be addressed on a global level. The answers to these
questions can be of significant value in updating and revis-
ing the current guidelines and improving patient care.
The World Allergy Organization (WAO) Junior Mem-
bers Group (JMG) Steering Committee developed a ques-
tionnaire to survey the opinions on a whole variety of
questions regarding CSU management and the use of
guidelines. The questionnaire targeted the WAO members,
including, but not limited to the representatives of the con-
stituent national societies of WAO, having the authority to
vote on their behalf, the WAO JMG and the American
Academy of Allergy, Asthma & Immunology (AAAAI)
members. We sought to determine, in physicians from
around the world, the knowledge of and adherence to inter-
national and national urticaria guidelines as well as the mo-
tives to deviate from them.
Methods
Study survey
A web-based questionnaire (Additional file 1: Figure S1)
was created and circulated among the members of the
WAO JMG Steering Committee for revisions (July–Sep-
tember 2016). The protocol was approved by the WAO
Executive Committee and Board of Directors (25 October
2016). The questionnaire was created de novo and has not
been previously validated. The final version consisted of 24
questions including survey participant demographic infor-
mation (country of residence, gender, age, specialty, clinical
experience and type of practice) and those concerning CSU
management (patients’ age, number of CSU patients seen
per week, number of CSU patients with angioedema,
awareness, adherence and/or deviation of current guide-
lines, examination of a CSU patient, including general
laboratory work-up and targeted search for the cause of the
disease, and treatment options used). There were 11
single-choice and 13 multiple-choice questions.
Recruitment and dissemination
The survey was beta tested and approved by the WAO
JMG Steering Committee and WAO leadership before
dissemination among participants. It was disseminated via
email by the WAO office to representatives of WAO
Member Societies as well as members of AAAAI and the
WAO JMG in March 2017, with no restrictions applied to
the specialty, affiliation, or nationality of the participants.
The email contained a link (Internet address) to the online
questionnaire that was unique to each participating
member. A reminder to participate was sent in April 2017.
Participants were given 30 days to reply and were guaran-
teed complete anonymity.
Statistical analysis
SPSS v.22 (Armonk, NY: IBM Corp, USA) was used for all
analyses. Analyses of the difference in frequencies across
groups were performed with the Pearson Chi-squared test
and a p value ≤0.05 was considered significant.
Results
Demographics of study participants
A total of 32,356 individuals from 149 countries were
invited to take part in the survey. We received 1140
(3.5%) completed surveys from participating physicians
from 99 countries, with most residing in Europe (33.2%)
and North America (28.9%) (Table 1). Most of the
respondents were allergists/clinical immunologists
(88.7%), followed by pediatricians (16.5%), dermatolo-
gists (4.5%) and general practitioners (2.2%) (Table 2).
One hundred and fifty-seven participants had more than
one specialty. The majority of participants were ≥
40 years old (74.8%) and almost half of respondents had
clinical experience of > 19 years (43.9%). Two thirds and
half of the participants worked in academic institutions
and/or had a private practice. Most participants (88.9%)
reported to see primarily outpatients, both adults and
children with CSU (53.7%). Only 22% of physicians
reported to see ≥10 CSU patients per week.
More than 90% of physicians follow the urticaria
guidelines, but almost one-fourth of them deviate
Virtually all participants (1086 of 1126, 96%) were aware
of one or more urticaria guidelines, and almost all of them
reported to follow a guideline (n = 1038 of 1086, 96%)
(Fig. 1). The most widely used guideline was the inter-
national EAACI/GA2LEN/EDF/WAO urticaria guideline
[1] (58.9%), followed by the American AAAAI/ACAAI
Joint Task Force practice parameters for the diagnosis and
management of acute and chronic urticaria [7] (38.1%)
and national guidelines (22.7%). Expectedly, the US Joint
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Table 1 A geographical distribution of the respondents participating in the survey (n = 1140)
North America
(n = 330, 28.9%)
Latin America
(n = 193, 16.9%)
Europe
(n = 379, 33.2%)
Africa/Middle-East
(n = 64, 5.6%)
Asia-Pacific
(n = 174, 15.3%)
Canada Argentina Albania Algeria Australia
United States Bolivia Armenia Cyprus Bangladesh
US Virgin Islands Brazil Austria Egypt Cambodia
Chile Azerbaijan Ethiopia Hong Kong
Colombia Belarus Iran India
Costa Rica Belgium Israel Indonesia
Cuba Bulgaria Kenya Japan
Dominican Republic Croatia Lebanon Jordan
Ecuador Czech Republic Oman Korea
El Salvador Denmark Qatar Kuwait
Guatemala Estonia South Africa Malaysia
Honduras Finland Tunisia Mongolia
Mexico France Nepal
Panama Georgia New Zealand
Paraguay Germany Pakistan
Peru Greece Peoples Republic of China
Uruguay Guernsey Philippines
Venezuela Hungary Saudi Arabia
Iceland Singapore
Ireland Sri Lanka
Italy Taiwan
Kosovo Thailand
Latvia United Arab Emirates
Lithuania Uzbekistan
Macedonia Viet Nam
Moldova
Montenegro
Netherlands
Poland
Portugal
Romania
Russia
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Turkey
Ukraine
United Kingdom
Kolkhir et al. World Allergy Organization Journal  (2018) 11:14 Page 3 of 13
Table 2 Characteristics of survey respondents (n = 1140)
Characteristics of respondents Geographical regions Total
% (n)NA
% (n/total)
LA
% (n/total)
EU
% (n/total)
AME
% (n/total)
AP
% (n/total)
Specialtya (n = 1138)
Allergists/ Clinical Immunologists 98.2 (324/330) 97.4 (187/192) 83.1 (315/379) 79.7 (51/64) 76.9 (133/173) 88.7 (1010)
Dermatologists 0.3 (1/330) 0.5 (1/192) 9.8 (37/379) 0 6.9 (12/173) 4.5 (51)
Pediatricians 4.2 (14/330) 25.5 (49/192) 17.4 (66/379) 23.4 (15/64) 25.4 (44/173) 16.5 (188)
General Practitioners 0.6 (2/330) 3.1 (6/192) 1.6 (6/379) 6.2 (4/64) 4 (7/173) 2.2 (25)
Gender (n = 1117)
Male 58.5 (189/323) 55.1 (102/185) 43.7 (163/373) 57.1 (36/63) 58.4 (101/173) 53.0 (591)
Female 41.5 (134/323) 44.9 (83/185) 56.3 (210/373) 42.9 (27/63) 41.6 (72/173) 47.0 (526)
Age, years (n = 1132)
< 40 22.9 (75/327) 27.6 (53/192) 28.2 (106/376) 17.2 (11/64) 23.1 (133/173) 25.2 (285)
≥40 77.1 (252/327) 72.4 (139/192) 71.8 (270/376) 82.8 (53/64) 76.9 (133/173) 74.8 (847)
Clinical experience, years (n = 1130)
≤19 50.3 (164/326) 53.9 (104/193) 58.2 (217/373) 60.9 (39/64) 63.2 (110/174) 56.1 (634)
Over 19 49.7 (162/326) 46.1 (89/193) 41.8 (156/373) 39.1 (25/64) 36.8 (64/174) 43.9 (496)
Place of worka (n = 1140)
Private practice 63.9 (211/330) 82.4 (159/193) 34.6 (131/379) 54.7 (35/64) 46.0 (80/174) 54.0 (616)
University clinic 70.3 (232/330) 68.4 (132/193) 57.5 (218/379) 59.4 (38/64) 71.8 (125/174) 65.3 (745)
Hospital 11.8 (39/330) 39.4 (76/193) 43.3 (164/379) 42.2 (27/64) 58.6 (102/174) 35.8 (408)
Specialized urticaria centre 0.9 (3/330) 4.7 (9/193) 2.9 (11/379) 3.1 (2/64) 0.3 (3/174) 2.4 (28)
Department (n = 1140)
Outpatients 97.3 (321/330) 89.6 (173/193) 82.3 (312/379) 81.3 (52/64) 89.1 (155/174) 88.9 (1013)
Inpatients 0.9 (3/330) 8.8 (17/193) 12.4 (47/379) 10.9 (7/64) 6.9 (12/174) 7.5 (86)
Outpatients and inpatients 1.8 (6/330) 1.6 (3/193) 5.3 (20/379) 7.8 (5/64) 4.0 (7/174) 3.6 (41)
Age of patients (n = 1131)
Adults 16.5 (54/327) 17.2 (33/192) 42.0 (158/376) 10.9 (7/64) 30.8 (53/172) 27.0 (305)
Children 9.5 (31/327) 16.7 (32/192) 19.4 (73/376) 18.8 (12/64) 27.9 (71/172) 19.3 (219)
Adults and children 74.0 (242/327) 66.1 (127/192) 38.6 (145/376) 70.3 (45/64) 41.3 (48/172) 53.7 (607)
Number of CSU patients per week (n = 1127)
< 10 75.5 (247/327) 78.8 (152/193) 80.7 (302/374) 71.0 (44/62) 78.4 (134/171) 78.0 (879)
≥10 24.5 (80/327) 21.2 (41/193) 19.3 (72/374) 29.0 (18/62) 21.6 (37/171) 22.0 (248)
Patients with angioedema, % from the total number
of CSU patients (n = 1131)
≤20 37.7 (123/326) 58.5 (113/193) 51.7 (195/377) 55.6 (35/63) 66.3 (114/172) 51.3 (580)
> 20 62.3 (203/326) 41.5 (80/193) 48.3 (182/377) 44.4 (28/63) 33.7 (58/172) 48.7 (551)
Adherence to the urticaria guidelinesa (n = 1126)
Follow the guidelines Any of three below 88.0 (286/325) 93.8 (180/192) 97.3 (365/375) 85.7 (54/63) 89.5 (153/171) 92.2 (1038)
EAACI/WAO/GA2LEN/EDF 16.3 (53/325) 78.1 (150/192) 82.4 (309/375) 68.3 (43/63) 63.2 (108/171) 58.9 (663)
US practice parameters 81.2 (264/325) 32.3 (62/192) 9.1 (34/375) 28.6 (18/63) 29.8 (51/171) 38.1 (429)
National 7.1 (23/325) 26.0 (50/192) 32.5 (122/375) 14.3 (9/63) 30.4 (52/171) 22.7 (256)
Follow any but deviate 40.0 (80/200) 28.1 (25/89) 49.4 (79/160) 58.1 (18/31) 53.8 (49/91) 22.3 (251)
Do not follow 12.0 (39/325) 6.3 (12/192) 2.7 (10/375) 14.3 (9/63) 10.5 (18/171) 7.8 (88)
AME Africa/Middle-East, AP Asia-Pacific, EU Europe, LA Latin America, NA North America. arespondents could choose more than one option
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Task Force practice parameters are used more often
in North America and the EAACI/GA2LEN/EDF/
WAO urticaria guidelines are more known in other
countries of the world. One in five physicians who
follow a guideline (22%) reported to deviate from it.
Reliance on own clinical experience is the most frequent
reason for deviation from the guidelines or not following
them
Of the 339 (30%) physicians who do not follow a
guideline or follow a guideline but deviate from it,
149 (43.9%) reported that they rely more on their
own clinical experience (Table 3). It was the most fre-
quent reason in all regions of the world except for
Latin America, where the most common reason, pro-
vided by 14.3% of respondents, was that some of the
guidelines’ recommendations cannot be implemented
in their country of residence. The second most preva-
lent reason for deviating from guideline recommenda-
tions (29.8%) was that the approach to CSU
management recommended by the guidelines was
seen as overly simplified and not reflecting the com-
plexity of the disease. The least frequent reasons were
the discrepancy and/or disagreement between the
guidelines (3.8%) and a negative experience with
following the guidelines in clinical practice (3.2%).
Nine percent of participants did not agree with the
guidelines’ recommendations and/or conclusions.
Young and less experienced physicians more often follow
a guideline and less often deviate than older and
experienced ones
Physicians who are less than 40 years of age more
often reported that they adhere to urticaria guidelines and
less often deviate as compared to responding physicians of
≥40 years of age (p = 0.001 and p = 0.023, respectively).
Responding physicians with clinical experience of > 19
years statistically more often deviate from the guide-
lines and less frequently follow them as compared to
responding physicians with clinical experience of
19 years or less (p = 0.025 and p < 0.001, respectively)
(Tables 4 and 5).
Physicians who follow a urticaria guideline more often
perform diagnostic tests
Physicians who follow a urticaria guideline showed higher
rates of routinely ordering a complete blood count (CBC),
Fig. 1 Adherence to the urticaria guidelines. Physicians were asked if
they know and follow the current guidelines for management of
urticaria. Results are expressed as percentage of participants who
chose the corresponding guidelines (one respondent could choose
several answers)
Table 3 Reasons why physicians don’t follow or deviate from the guidelines
Reasons Geographical regions Total n = 339a
% (n)NA n = 236a
% (n)
LA n = 98a
% (n)
EU n = 167a
% (n)
AME n = 38a
% (n)
AP n = 104a
% (n)
The guidelines do not undergo revision frequently enough 4.2 (10) 4.1 (4) 3.0 (5) 5.3 (2) 6.7 (7) 8.2 (28)
I rely more on my own clinical experience 27.1 (64) 10.2 (10) 20.4 (34) 34.2 (13) 26.9 (28) 43.9 (149)
I do not agree with the guidelines’ recommendations
and/or conclusions
7.2 (17) 3.1 (3) 4.2 (7) 2.6 (1) 3.8 (4) 9.4 (32)
Some of the recommendations are unclear to me and require
further details
3.4 (8) 1.0 (1) 8.4 (14) 2.6 (1) 11.5 (12) 10.6 (36)
Some of the guidelines’ recommendations cannot be
implemented in my country of residence
0.8 (2) 14.3 (14) 12.0 (20) 26.3 (10) 22.1 (23) 20.3 (69)
I had a negative experience with following the guidelines
in my clinical practice
1.7 (4) 0 (0) 3.6 (6) 2.6 (1) 0 (0) 3.2 (11)
Overly simplified approach to CSU management
recommended by the guidelines that does not
reflect the complexity of the disease
22.9 (54) 7.1 (7) 15.6 (26) 10.5 (4) 9.6 (10) 29.8 (101)
The discrepancy and/or disagreement between the guidelines 3.0 (7) 2.0 (2) 1.8 (3) 2.6 (1) 0 (0) 3.8 (13)
AME Africa/Middle-East, AP Asia-Pacific, EU Europe, LA Latin America, NA North America. athe total number of respondents was 339. However, there was
overlapping in the data analysis because respondents could choose more than one option
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the erythrocyte sedimentation rate (ESR), C-reactive pro-
tein (CRP), anti-thyroid antibodies, and thyroid-stimulating
hormone (TSH) and of performing the autologous serum
skin test (ASST) as compared to those who do not (Table 6).
CSU due to unknown causes was reported to be much
more common than CSU due to known causes, in all
regions of the world (90 vs 10%). Autoimmunity was
the most common identifiable cause of CSU (51.9%)
and malignancy was the least common identifiable
cause of CSU (4.5%). Food intolerance was a less fre-
quent cause of CSU in North America (8.0%) as com-
pared to other regions of the world (> 16.0%) (Table 7).
Table 4 Factors linked to adherence to the urticaria guidelines
Factors % (n) of physicians, who follow the guidelines % (n) of physicians, who don’t follow the guidelines X2 p
Age, years
< 40 (n = 283) 96.9 (274) 3.1 (9) 11.152 0.001
≥40 (n = 836) 90.7 (758) 9.3 (78)
Clinical experience, years
≤19 years (n = 630) 95.9 (604) 4.1 (26) 28.017 < 0.001
Over 19 years (n = 487) 87.3 (425) 12.7 (62)
Departmenta
Outpatients (n = 1006) 92.0 (926) 8.0 (80/85) 0.431 0.511
Inpatients (n = 84) 94.0 (79) 6.0 (5)
Age of patientsa
Adults (n = 300) 92.3 (277) 7.7 (23) 0.029 0.865
Children (n = 193) 92.7 (179) 7.3 (14)
CSU patients per week
< 10 (n = 870) 92.2 (802) 7.8 (68) 0.076 0.783
≥10 (n = 247) 92.7 (229) 7.3 (18)
aOnly in physicians who chose one of the options
Values marked in bold indicate a statistically significant difference (p < 0.05)
Table 5 Factors linked to the deviation from the urticaria guidelines
Factors % (n) of physicians, who
deviate from the guidelines
% (n) of physicians, who don’t
deviate from the guidelines
X2 p
Age, years
< 40 (n = 140) 35.7 (50) 64.3 (90) 5.194 0.023
≥40 (n = 428) 46.7 (200) 53.3 (228)
Clinical experience, years
≤19 years (n = 323) 39.9 (129) 60.1 (194) 5.049 0.025
Over 19 years (n = 245) 49.4 (121) 50.6 (124)
Patientsa
Outpatients (n = 510) 44.5 (227) 55.5 (283) 0.029 0.865
Inpatients (n = 44) 43.2 (19) 56.8 (25)
Age of patientsa
Adults (n = 150) 55.3 (83) 44.7 (67) 7.712 0.005
Children (n = 92) 37.0 (34) 63.0 (58)
CSU patients per week
< 10 (n = 441) 44.0 (194) 50.0 (247) 0.002 0.961
≥10 (n = 128) 43.7 (56) 56.3 (72)
aOnly in physicians who chose one of the options
Values marked in bold indicate a statistically significant difference (p < 0.05)
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Adherence to urticaria guidelines is associated with more
frequent administration and confidence in higher efficacy
of second-generation antihistamines
Updosing of second-generation H1-antihistamines
(sgAHs, 97%) and omalizumab (96%) were reported to
be the most effective treatment options in all regions of
the world. Dapsone, montelukast and H2-antihistamines
were considered effective drugs for treatment of CSU
worldwide only by 17, 17 and 15% physicians, respect-
ively. Less respondents from North America as com-
pared to other regions of the world reported that
sgAHs at standard dose and montelukast are highly ef-
fective (48% vs 60–76 and 9% vs 13–35%, respectively).
Vice versa, more physicians from North America as
compared to other countries reported that tricyclic an-
tidepressants are highly effective (52% vs 15–33%). Phy-
sicians who follow a urticaria guideline showed higher
rates of sgAHs administration as a first-line treatment
of CSU (p = 0.001) and more frequently observed
higher efficacy of treatment (or had more confidence
that it would work, p < 0.019) as compared to those who
do not follow the guidelines (Table 8). Guideline fol-
lowers more frequently use higher than standard-dosed
sgAHs and omalizumab as a second and third line
treatment, respectively, and less frequently administer first
generation antihistamines, tricyclic antidepressants and
Table 6 Differences in the approach to the management of CSU in respondents who do and do not follow the guidelines
Test Compared groups n % (n) of physicians, who
follow the guidelines
% (n) of physicians, who
don’t follow the guidelines
X2 p
CBC Order 854 79.2 (802) 60.5 (52) 16.011 < 0.001
No 245 20.8 (211) 39.5 (34)
ESR Order 602 55.9 (566) 41.9 (36) 6.284 0.012
No 497 44.1 (447) 58.1 (50)
CRP Order 527 49.0 (496) 36.0 (31) 5.299 0.021
No 572 51.0 (517) 64.0 (55)
Anti-TG/TPO Order 559 51.9 (526) 38.4 (33) 5.826 0.016
No 540 48.1 (487) 61.6 (53)
TSH Order 543 50.8 (515) 32.6 (28) 10.598 0.001
No 556 49.2 (498) 67.4 (58)
Total IgE Order 481 56.1 (445) 58.1 (36) 0.138 0.710
No 618 43.9 (568) 41.9 (50)
ECP Order 51 4.7 (48) 3.5 (3) 0.280 0.597
No 1048 95.3 (965) 96.5 (83)
D-dimer Order 54 5.2 (53) 1.2 (1) 2.809 0.094
No 1045 94.8 (960) 98.8 (85)
Skin prick tests Order 308 71.4 (290) 79.1 (18) 2.329 0.127
No 791 28.6 (723) 20.9 (68)
Allergen-specific IgE Order 286 26.5 (268) 20.9 (18) 1.257 0.262
No 813 73.5 (745) 79.1 (68)
ANA Order 407 37.7 (382) 29.1 (25) 2.538 0.111
No 692 62.3 (631) 70.9 (61)
Tryptase Order 162 84.9 (153) 89.5 (9) 1.357 0.244
No 937 15.1 (860) 10.5 (77)
ASST Order 186 17.7 (179) 8.1 (7) 5.121 0.024
No 913 82.3 (834) 91.9 (79)
Search for chronic infections Perform 364 66.2 (342) 74.4 (22) 2.394 0.122
No 735 33.8 (671) 25.6 (64)
Do not order any tests 182 15.4 (156) 30.2 (26) 12.621 < 0.001
Order at least 1 test 917 84.6 (857) 69.8 (60)
CBC complete blood count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TG/TPO thyroglobulin/thyroperoxidase, TSH thyroid-stimulating hormone,
ECP eosinophil cationic protein, ANA antinuclear antibodies, ASST autologous serum skin test
Values marked in bold indicate a statistically significant difference (p < 0.05)
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systemic corticosteroids in comparison to physicians who
do not follow a urticaria guideline (Tables 9 and 10).
Discussion
Several guidelines, consensus papers, and practice pa-
rameters have been developed for the management of
chronic urticaria. Some studies have explored, on the na-
tional level, if physicians know these guidelines and im-
plement them in their actual clinical practice [8, 9]. To
our knowledge, our study is the first global report of
how physicians approach CSU.
Most physicians know and use urticaria guidelines in their
clinical practice
More than 90% of respondents stated to be aware
and follow urticaria guidelines. However, there is in-
consistency between our study and other studies. For
example, most respondents from Latin America in
Table 8 Differences in the approach to a first line treatment of CSU in physicians who do and do not follow the guidelines
Treatment Compared
groups
n % (n) of physicians, who
follow the guidelines
% (n) of physicians, who
don’t follow the guidelines
X2 p
First-generation H1-antihistamines Administer 173 15.4 (160) 14.8 (13) 0.026 0.873
No 953 84.6 (878) 85.2 (75)
Second-generation H1-antihistamines at standard
dose
Administer 704 64 (664) 45.5 (40) 11.868 0.001
No 422 36 (374) 54.5 (48)
Updosed second-generation H1-antihistamines Administer 540 47.8 (496) 50.0 (44) 0.160 0.690
No 586 52.2 (542) 50.0 (44)
H2-antihistamines (e.g. famotidine or ranitidine) Administer 224 19.7 (204) 22.7 (20) 0.481 0.488
No 902 80.3 (834) 77.3 (68)
Ciclosporin Administer 15 1.4 (15) 0 1.289 0.256
No 1111 98.6 (1023) 100 (88)
Omalizumab Administer 32 3.0 (31) 1.1 (1) 1.006 0.316
No 1094 97.0 (1007) 98.9 (87)
Montelukast Administer 150 13.2 (137) 14.8 (13) 0.174 0.676
No 976 86.8 (901) 85.2 (75)
Dapsone Administer 7 0.6 (6) 1.1 (1) 0.409 0.522
No 1119 99.4 (1032) 98.9 (87)
Systemic corticosteroids (for less than 10 days) Administer 215 18.7 (194) 23.9 (21) 1.406 0.236
No 911 81.3 (844) 76.1 (67)
Systemic corticosteroids (for more than 10 days
in a row)
Administer 16 1.5 (16) 0 1.376 0.241
No 1110 98.5 (1022) 100 (88)
Tricyclic antidepressants (e.g. doxepin) Administer 35 3.0 (31) 4.5 (4) 0.655 0.418
No 1091 97.0 (1007) 95.5 (84)
Values marked in bold indicate a statistically significant difference (p < 0.05)
Table 7 Number of respondents from different regions of the world who find these causes of CSU as most common (n = 1098)a
CSU causes Geographical regions Total
% (n/total)NA
% (n/total)
LA
% (n/total)
EU
% (n/total)
AME
% (n/total)
AP
% (n/total)
Idiopathic CSU 97.5 (315/323) 80.6 (150/186) 88 (323/367) 93.3 (56/60) 89.5 (145/162) 90.1 (989/1098)
Type-I-allergy 27.5 (77/280) 27.1 (46/170) 17.9 (60/336) 19.6 (11/56) 39.6 (59/149) 25.5 (253/991)
Autoimmune CSU 64.4 (201/312) 44.8 (81/181) 46.8 (166/355) 32.8 (19/58) 54.1 (80/148) 51.9 (547/1054)
Systemic disorders 26.7 (79/296) 29.1 (50/172) 18.2 (62/340) 12.3 (7/57) 20.8 (31/149) 22.6 (229/1014)
Malignancy 2.4 (7/288) 6.1 (10/165) 6.6 (22/334) 0 (0/56) 3.6 (5/139) 4.5 (44/982)
Chronic infection 11.7 (34/290) 32.8 (58/177) 27.4 (95/347) 13.6 (8/59) 22.3 (33/148) 22.3 (228/1021)
Food intolerance 8.0 (23/289) 19.7 (35/178) 16.3 (56/343) 22.4 (13/58) 26.6 (41/154) 16.4 (168/1022)
AME Africa/Middle-East, AP Asia-Pacific, EU Europe, LA Latin America, NA North America. athe respondents could choose more than one answer
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our study (94%) followed any urticaria guideline with
78% followed the EAACI/GA2LEN/EDF/WAO urti-
caria guideline. In contrast, only 79 of 421 (19%) phy-
sicians from Ecuador reported to know the EAACI/
GA2LEN/EDF/WAO urticaria guideline, but more
than half of them (67%) were dermatologists and al-
lergists [8]. In German-wide study, only one-third of
all physicians participating in the survey were familiar
with the EAACI/GA2LEN/EDF/WAO urticaria guide-
line [9]. In Italy, 56% of specialists knew the CSU
guidelines and only 27% used them regularly [10].
The high rates of adherence to urticaria guidelines in
our study can be explained by increase in guidelines
awareness worldwide over time and the fact that most
of the participants were allergists/clinical immunolo-
gists (88%).
Factors associated with adherence to guidelines
Young (< 40 years) and less experienced physicians
(≤19 years in practice) more often follow guidelines and
less often deviate from them than their older and more
experienced colleagues. A similar tendency has been ob-
served for other diseases, where low adherence rates to
guidelines were also showed to be linked with the ad-
vanced age of the physicians [11–13]. For example, old
age, male sex, and incomplete residency training were
associated with disagreement with clinical practice
guidelines for cancer screening [13]. In contrast, com-
pared with physicians ≥50 years, younger physicians (<
50 years) reported a lower level of awareness of choles-
terol guidelines [14].
We did not compare the adherence to urticaria guide-
lines between respondents of different specialties be-
cause most physicians in our study were allergists and
many of them had several specialties. However, in previ-
ous studies the level of knowledge was highest for aller-
gists and/or dermatologists [8, 9], and these physicians
have significantly higher expertise in caring for patients
with urticaria than other specialists [15]. An observa-
tional study from the UK showed that allergists follow
the urticaria guidelines more regularly and consistently
compared to dermatologists [16]. The results of this
study should be evaluated with caution because of the
fact that Allergology is recognized as a specialty in some
countries (for example, in Russia) or as a subspecialty in
others (for example, in Germany).
Table 9 Differences in the approach to a second line treatment of CSU in physicians who do and do not follow the guidelines
Treatment Compared
groups
n % (n) of physicians, who
follow the guidelines
% (n) of physicians, who
don’t follow the guidelines
X2 p
First-generation H1-antihistamines Administer 156 13.1 (136) 22.7 (20) 6.297 0.012
No 970 86.9 (902) 77.3 (68)
Second-generation H1-antihistamines at standard
dose
Administer 127 11.3 (117) 11.4 (10) 0.001 0.979
No 999 88.7 (921) 88.6 (78)
Updosed second-generation H1-antihistamines Administer 651 58.8 (610) 46.6 (41) 4.931 0.026
No 475 41.2 (428) 53.4 (47)
H2-antihistamines (e.g. famotidine or ranitidine) Administer 308 27.1 (281) 30.7 (27) 0.532 0.466
No 818 72.9 (757) 69.3 (61)
Ciclosporin Administer 76 6.8 (71) 5.7 (5) 0.173 0.678
No 1050 93.2 (967) 94.3 (83)
Omalizumab Administer 163 14.5 (150) 14.8 (13) 0.007 0.934
No 963 85.5 (888) 85.2 (75)
Montelukast Administer 391 35.5 (368) 26.1 (23) 3.106 0.078
No 735 64.5 (670) 73.9 (65)
Dapsone Administer 39 3.2 (33) 6.8 (6) 3.213 0.073
No 1087 96.8 (1005) 93.2 (82)
Systemic corticosteroids (for less than 10 days) Administer 265 23.8 (247) 20.5 (18) 0.503 0.478
No 861 76.2 (791) 79.5 (70)
Systemic corticosteroids (for more than 10 days
in a row)
Administer 89 7.4 (77) 13.6 (12) 4.309 0.038
No 1037 92.6 (961) 86.4 (76)
Tricyclic antidepressants (e.g. doxepin) Administer 137 11.6 (120) 19.3 (17) 4.568 0.033
No 989 88.4 (918) 80.7 (71)
Values marked in bold indicate a statistically significant difference (p < 0.05)
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Impact of following the guidelines on the quality of care
for CSU patients
According to the EAACI/GA2LEN/EDF/WAO guideline,
only differential blood count and CRP or ESR are rec-
ommended as routine diagnostic tests for CSU patients
[1]. The US practice parameters recommend limited la-
boratory testing including a CBC with differential, ESR
and/or CRP, liver enzymes, and TSH measurement [7].
Expectedly, these diagnostic tests were performed more
frequently by physicians who follow a urticaria guideline
in our and other studies [8, 9].
Additional tests are indicated as an extended diag-
nostic program for identification of underlying causes
or eliciting factors and for ruling out possible differ-
ential diagnoses if suggested based on history only
[1]. For example, allergy is regarded as a very rare
cause of CSU [1], and allergy testing is usually not
cost-effective and does not lead to improved patient
care outcomes [7]. However, some physicians reported
to determine total serum IgE (43.8%) and to perform
allergy skin prick testing in patients with CSU
(28.0%). In a cross-sectional study from Latin Amer-
ica, total serum IgE was the most common diagnostic
test (83.5%) [8]. Interestingly, 5–15% of respondents
perform other less useful diagnostic tests, e.g. ECP
and tryptase, in patients with CSU.
Idiopathic CSU was reported to be the most common
type of CSU; this is in the line with other studies [9, 17].
In one study, allergists and dermatologists more fre-
quently searched for CSU etiology as compared to gen-
eral practitioners [8] in contrast to the results of other
study [9]. Although IgE-mediated allergy is a rare cause
of CSU [1, 18], IgE-mediated allergy is considered to be
a common cause of CSU by 26% of respondents.
Up to 50% of CSU patients can have circulating func-
tional IgG autoantibodies against IgE and high-affinity
IgE receptors on mast cells and basophils [19]. Half of
respondents reported autoimmune CSU as the most
common cause of CSU and 16.9% of physicians (10.1–
13.5% in other studies [8, 9]) carried out ASST as a
screening method for the detection of autoantibodies
[1]. ASST was applied more often by physicians who
were aware of and/or follow the guidelines in our and
another study [9], but not in all [8].
There is a universal agreement among urticaria guide-
lines [1, 7, 20] that second generation antihistamines
Table 10 Differences in the approach to a third line treatment of CSU in physicians who do and do not follow the guidelines
Treatment Compared groups n % (n) of physicians, who
follow the guidelines
% (n) of physicians, who
don’t follow the guidelines
X2 p
First-generation H1-antihistamines Administer 93 7.7 (80) 14.8 (13) 5.345 0.021
No 1033 92.3 (958) 85.2 (75)
Second-generation H1-antihistamines at standard
dose
Administer 78 6.9 (72) 6.8 (6) 0.002 0.967
No 1048 93.1 (966) 93.2 (82)
Updosed second-generation H1-antihistamines Administer 283 25.4 (264) 21.6 (19) 0.637 0.425
No 843 74.6 (774) 78.4 (69)
H2-antihistamines (e.g. famotidine or ranitidine) Administer 206 18.3 (190) 18.2 (16) 0.001 0.977
No 920 81.7 (848) 81.8 (72)
Ciclosporin Administer 254 23.1 (240) 15.9 (14) 2.416 0.120
No 872 76.9 (798) 84.1 (74)
Omalizumab Administer 570 51.8 (538) 36.4 (32) 7.764 0.005
No 556 48.2 (500) 63.6 (56)
Montelukast Administer 319 28.9 (300) 21.6 (19) 2.135 0.144
No 807 71.1 (738) 78.4 (69)
Dapsone Administer 91 7.8 (81) 11.4 (10) 1.384 0.239
No 1035 92.2 (957) 88.6 (78)
Systemic corticosteroids (for less than 10 days) Administer 227 20.1 (209) 20.5 (18) 0.005 0.943
No 899 79.9 (829) 79.5 (70)
Systemic corticosteroids (for more than 10 days
in a row)
Administer 146 12.7 (132) 15.9 (14) 0.733 0.392
No 980 87.3 (906) 84.1 (74)
Tricyclic antidepressants (e.g. doxepin) Administer 134 11.7 (121) 14.8 (13) 0.751 0.386
No 992 88.3 (917) 85.2 (75)
Values marked in bold indicate a statistically significant difference (p < 0.05)
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(sgAHs) at a standard dose should be the first line therapy,
which is effective in improving symptoms in about 40% of
CSU patients [21]. Guideline followers, quite expectedly,
use sgAHs at a standard dose as a first line therapy more
frequently than non-followers, while the administration of
other drugs was not different between the two groups.
This has been proved in early national cross-sectional
studies where sgAHs taken regularly were the most com-
mon drugs prescribed [10, 22]. It is consistent with the
finding that more guidelines followers (67.4%) than
non-followers (50%) feel that sgAHs are highly effective in
CSU treatment.
As a second line therapy, the EAACI/GA2LEN/EDF/
WAO urticaria guideline recommends the use of sgAHs
in higher doses up to four times the standard dose. Phy-
sicians who use urticaria guidelines more frequently se-
lected up-dosing for a second-line treatment in our and
other studies [9, 10].
For non-respondents to sgAHs up-dosing, the EAACI/
GA2LEN/EDF/WAO guideline recommends omalizu-
mab, ciclosporin (step 4 in the US practice parameters)
or montelukast (step 2 in the US practice parameters) as
a third line treatment option [1, 7]. Guideline followers
in our and one other study [8] more frequently used
omalizumab as a third line treatment in comparison to
physicians who do not follow a urticaria guideline.
Our and early studies [9] showed that physicians who
are familiar with the guidelines are less likely to use first
generation antihistamines as a second and/or third line
treatment and systemic steroids (for more than 10 days in
a row) as a second line therapy, indicating that guideline
recommendations may improve the quality of care [9].
The treatment of CSU can depend on physician’s spe-
cialty. For example, Cherrez et al. showed that allergists
and dermatologists in Ecuador prescribed significantly
more sgAHs (regular doses) as compared to general prac-
titioners [8].
Reasons for not following or deviation from the available
urticaria guidelines
Almost one-third of physicians do not follow a guideline
or deviate from it. The most frequent reasons given were
reliance on their own clinical experience (44%) and an
overly simplified approach to CSU management recom-
mended by the guidelines (30%). Moreover, many physi-
cians, especially those of 40 years or older and with
clinical experience of > 19 years, follow guidelines but
can deviate from them in some cases, e.g. in
difficult-to-treat CSU. This may point to a need to better
communicate to physicians, especially experienced phy-
sicians, the benefits of guideline adherence and to better
engage them in the guideline development and review
process. Also, more efforts appear to be needed to im-
prove physician “buy-in” to guidelines by allowing for
sufficient flexibility and by educating them that guide-
lines are meant to complement, rather than substitute
for, clinical judgement.
One-fifth of physicians reported that some of the guide-
lines’ recommendations cannot be implemented in physi-
cian’s country of residency. It suggests that economic
considerations are an important and often decisive factor
influencing the choice of a treatment strategy. For ex-
ample, omalizumab is unavailable in some countries or its
cost is too high and health insurance programs do not
cover it (for example, in Russia or Latin America [23]).
Systemic steroids and first generation antihistamines are
cheaper than sgAHs (for example, in Ecuador [8]) and this
can prompt a physician’s decision to prescribe them. The
cost-effectiveness of the treatment for CSU, especially in
the developing and low-income countries, should be fur-
ther investigated in future studies.
The EAACI/GA2LEN/EDF/WAO guideline is revised
every four years by a global panel of well-known experts
in the field. Interestingly, 8–10% of respondents did not
agree with guidelines’ recommendations and conclusions
or found guideline recommendations unclear or out-
dated. Again, this calls for the consideration of improve-
ments in the development of guideline updates and
revisions.
The recommendations given by all of urticaria guidelines
are similar, although some differences exist. For example, in
contrast to the EAACI/GA2LEN/EDF/WAO guideline US
practice parameters recommend H2-antagonists and first
generation antihistamines for treatment of urticaria as a
second or third line therapy, respectively [24]. Only 4% of
respondents named the discrepancy and/or disagreement
between the guidelines as a reason not to follow them.
Taken together, reliance on own clinical experience, es-
pecially in older physicians, rather than economic reasons
or unavailability of drugs, appears to be the most frequent
reason for deviation from or not following the guidelines.
This observation offers the opportunity for a debate on
medicine based on experience and evidence-based medi-
cine and highlights the need for continuous medical edu-
cation for healthcare providers.
Limitations
The main limitations of our study are the bias of partici-
pant selection, the use of an online non-validated ques-
tionnaire and a low response rate (3.5%). The fact that
most participants in our study were allergists, whereas
CSU is often managed by dermatologists and general
practitioners, could explain some differences between our
findings and those from other studies [8, 9]. There is lim-
ited information in regards to CSU management in Af-
rica/Middle-East (only 64 questionnaires were filled out).
The most recent EAACI guideline [18] appeared after we
performed our study agreeing on our observations.
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Conclusion
The results of our study indicate that urticaria guideline
recommendations contribute to a higher quality of pa-
tient care. Most physicians worldwide follow a guideline,
however, one in five deviates from them. We speculate
there are three major reasons for deviation that should
be addressed in future research. Firstly, older physicians
may be prone to disproportionate reliance on their clin-
ical experience and unable to fully incorporate rapidly
emerging evidence-based approaches in their routine clin-
ical practice, which highlights the need for continuous
medical education for healthcare providers regardless of
their age group or occupying position. Secondly, the qual-
ity of CSU patient care may be, to a large degree, compro-
mised by the financial constraints and insufficient level of
training of the treating physicians in developing countries.
It warrants more research into pharmacoeconomics and
sustainability of up-to-date CSU treatments and further
propagation of new knowledge about CSU etiopathogen-
esis and treatment among practicing physicians of differ-
ent specialties and healthcare authorities in different
countries. Finally, urticaria guidelines themselves can be a
cause for suboptimal patient care (for example, unclear
recommendations and discrepancies between the guide-
lines). Thus, on the one hand, urticaria guidelines should
be flexible enough to allow a physician to tailor the treat-
ment to the unique profile of each patient and circum-
stances specific to their country of residence; on the
other hand, further standardization and dissemination of
guidelines can increase adherence among physicians
worldwide and result in better patient care.
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